Showing 1 - 10 of 10 Blood and Lymph Conditions

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Ashley Towne

Phone: 346.238.2006

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will ... Read more >

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Sharell Cornett-Risher

Phone: 713.441.3250

This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic a ... Read more >

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Sharell Cornett-Risher

Phone: 713.441.3250

This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone and in combination with various immunomodulatory agents in patients with relapsed/refractory multiple myeloma or patients with myeloma who have measureabl ... Read more >

Status: Open Not Enrolling

Investigator: Monisha Singh

Study Coordinator: Ashley Towne

Phone: 346.238.2006

This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The patient population durin ... Read more >

Status: Enrolling

Investigator: Brian Bruckner

Study Coordinator: Deborah Barr

Phone: 713.441.3916

This study is evaluating the effectiveness of PleuraFlow System Active Clearance Technology (ACT) in the management of blood evacuation. The Pleuraflow System ACT is a guided wire with a distal loop that rests at the end of a chest tube. The sys ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Ashley Towne

Phone: 346.238.2006

Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >

Status: Open Not Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Ashley Towne

Phone: 346.238.2006

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >

Status: Open Not Enrolling

Investigator: Alpesh Shah

Study Coordinator: Patricia Brinegar

Phone: 713.441.3506

This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and OUS. A minimum of 40% of total patients will be enrolled in the US. This study will enroll patient ... Read more >

Status: Enrolling

Investigator: Alan Lumsden

Study Coordinator: Kim Donlon

Phone: 713.441.9394

This prospective, multicenter, single-arm clinical study will further evaluate the safety and effectiveness of Cook's permanent and retrievable inferior vena cava (IVC) filters (specifically, the Günther Tulip® Vena Cava Filter and Cook Celect® ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Sharell Cornett-Risher

Phone: 713.441.3250

This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 monotherapy and R-907 (rituximab in combination with CUDC-907) in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Dif ... Read more >